The United States Patent and Trademark Office (USPTO) has granted patent number 8,992,989 to Supernus Pharmaceuticals, Inc for its novel once-daily extended-release topiramate product, Trokendi XR. The patent provides protection for the product with expiration that is no earlier than 2027.
"We are very serious about securing intellectual property protection for our innovative products. We will continue to build our patent estate to provide our products with the protection they are entitled to. We now have patent protection on Oxtellar XR and Trokendi XR through four and six issued US patents, respectively," said Jack A. Khattar, president and CEO of Supernus.
Supernus has several additional patent applications for extended-release topiramate and extended-release oxcarbazepine pending in other geographic regions.
Trokendi XR is the first approved novel once-daily extended release formulation of topiramate for the treatment of epilepsy. Trokendi XR is an antiepileptic drug indicated for initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures; adjunctive therapy in patients 6 years of age and older with partial onset or primary generalized tonic-clonic seizures; and adjunctive therapy in patients 6 years of age and older with seizures associated with Lennox-Gastaut syndrome. The product is available in 25mg, 50mg, 100mg and 200mg extended-release capsules.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system(CNS) diseases.